Core Viewpoint - Organovo Holdings, Inc. reported preliminary unaudited cash and net cash utilization results for the fiscal year ending March 31, 2025, indicating a cash balance of approximately $11.3 million and net cash utilization of $2.0 - $2.2 million for the fourth quarter [1][2]. Financial Summary - The preliminary cash and cash equivalents balance as of March 31, 2025, was approximately $11.3 million [2]. - The net cash utilization during the fourth quarter from January 1, 2025, to March 31, 2025, was approximately $2.0 - $2.2 million [2]. Nasdaq Compliance Update - The company expects to meet all requirements for continued listing on the Nasdaq Capital Market, having closed above the $1.00 minimum bid price since March 21, 2025 [3]. - Nasdaq requires a minimum of 10 consecutive trading days where the stock closes at a minimum bid price of $1.00, which the company has achieved [3]. Future Milestone Payments - The company anticipates receiving a $5 million milestone payment within the next 12 months related to the start of a Phase 2 clinical trial for the FXR agonist recently sold [4]. - Future milestone payments associated with the FXR agonist could total up to $50 million, including the $5 million payment upon the commencement of the Phase 2 clinical trial [4]. Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs effective in three-dimensional (3D) human tissues for drug development [5]. - The company utilizes proprietary technology to create 3D human tissues that replicate key aspects of native human tissue composition, architecture, function, and disease [5].